Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001).
Hiroto MatsuiTatsuya IokaTsuyoshi TakahashiToru KawaokaYoshinari MaedaNoboru YaharaHidefumi KuboTaku NishimuraToshihiro InokuchiEijiro HaradaYoshitaro ShindoYukio TokumitsuMasao NakajimaTaro TakamiKatsuyoshi ItoHidekazu TanakaKimikazu HamanoHiroaki NaganoPublished in: Pancreas (2024)
Overall, NAC for BRPC in real-world setting might yield R0 resection rates similar to those reported in previous clinical studies. Development of safe regimens and management strategies that can maintain treatment intensity in geriatric patients is warranted.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- lymph node
- transcription factor
- sentinel lymph node
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- cross sectional
- rectal cancer
- radiation therapy
- high intensity
- combination therapy
- early stage
- replacement therapy